AP1689A - N-phenpropylclopentyl-substituted glutaramide derivatives as nep inhibitors for FSAD. - Google Patents

N-phenpropylclopentyl-substituted glutaramide derivatives as nep inhibitors for FSAD.

Info

Publication number: AP1689A
Authority: AP; ARIPO
Prior art keywords: optionally substituted; phenpropylclopentyl; fsad; substituted; nep inhibitors
Prior art date: 2001-03-28

Application number

APAP/P/2002/002467A

Other languages

English (en)

Other versions

AP2002002467A0 (en

Inventor

Stephen Challenger

Andrew Simon Cook

Adam Thomas Gillmore

Donald Stuart Middleton

David Cameron Pryde

Alan STROBIE

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-28

Filing date

2002-03-28

Publication date

2006-12-07

2001-03-28 Priority claimed from GB0107750A external-priority patent/GB0107750D0/en

2001-05-30 Priority claimed from GB0113112A external-priority patent/GB0113112D0/en

2001-08-17 Priority claimed from GB0120152A external-priority patent/GB0120152D0/en

2002-03-28 Application filed by Pfizer filed Critical Pfizer

2002-06-30 Publication of AP2002002467A0 publication Critical patent/AP2002002467A0/xx

2006-12-07 Application granted granted Critical

2006-12-07 Publication of AP1689A publication Critical patent/AP1689A/en

Links

239000003112 inhibitor Substances 0.000 title 1
RCCYSVYHULFYHE-UHFFFAOYSA-N pentanediamide Chemical class NC(=O)CCCC(N)=O RCCYSVYHULFYHE-UHFFFAOYSA-N 0.000 title 1
125000004452 carbocyclyl group Chemical group 0.000 abstract 2
125000004432 carbon atom Chemical group C* 0.000 abstract 2
125000000623 heterocyclic group Chemical group 0.000 abstract 2
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
125000001054 5 membered carbocyclic group Chemical group 0.000 abstract 1
125000004008 6 membered carbocyclic group Chemical group 0.000 abstract 1
201000001880 Sexual dysfunction Diseases 0.000 abstract 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000001153 fluoro group Chemical group F* 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000001301 oxygen Substances 0.000 abstract 1
125000004076 pyridyl group Chemical group 0.000 abstract 1
231100000872 sexual dysfunction Toxicity 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/82—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Gynecology & Obstetrics (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Dispersion Chemistry (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Furan Compounds (AREA)
Pyrane Compounds (AREA)
Quinoline Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

APAP/P/2002/002467A 2001-03-28 2002-03-28 N-phenpropylclopentyl-substituted glutaramide derivatives as nep inhibitors for FSAD. AP1689A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0107750A GB0107750D0 (en)	2001-03-28	2001-03-28	Novel pharmaceuticals
GB0113112A GB0113112D0 (en)	2001-05-30	2001-05-30	Novel pharmaceuticals
GB0120152A GB0120152D0 (en)	2001-08-17	2001-08-17	Novel pharmaceuticals

Publications (2)

Publication Number	Publication Date
AP2002002467A0 AP2002002467A0 (en)	2002-06-30
AP1689A true AP1689A (en)	2006-12-07

Family

ID=27256128

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/2002/002467A AP1689A (en)	2001-03-28	2002-03-28	N-phenpropylclopentyl-substituted glutaramide derivatives as nep inhibitors for FSAD.

Country Status (33)

Country	Link
EP (1)	EP1373192A1 (is)
JP (1)	JP4018545B2 (is)
KR (1)	KR100564466B1 (is)
CN (1)	CN1243723C (is)
AP (1)	AP1689A (is)
AR (1)	AR035795A1 (is)
BG (1)	BG108130A (is)
BR (1)	BR0208455A (is)
CA (1)	CA2437113A1 (is)
CZ (1)	CZ20032534A3 (is)
DO (1)	DOP2002000364A (is)
EA (1)	EA006154B1 (is)
EE (1)	EE200300469A (is)
GE (1)	GEP20063783B (is)
HR (1)	HRP20030751A2 (is)
HU (1)	HUP0303624A3 (is)
IL (1)	IL157009A0 (is)
IS (1)	IS6877A (is)
MA (1)	MA26996A1 (is)
MX (1)	MXPA03006597A (is)
MY (1)	MY134081A (is)
NO (1)	NO20034299L (is)
NZ (1)	NZ527012A (is)
OA (1)	OA12553A (is)
PA (1)	PA8542401A1 (is)
PE (1)	PE20021014A1 (is)
PL (1)	PL365101A1 (is)
RS (1)	RS75303A (is)
SK (1)	SK11822003A3 (is)
TN (1)	TNSN02032A1 (is)
TW (1)	TWI254038B (is)
UY (1)	UY27227A1 (is)
WO (1)	WO2002079143A1 (is)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040014761A1 (en) *	1997-10-28	2004-01-22	Place Virgil A.	Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US7183410B2 (en)	2001-08-02	2007-02-27	Bidachem S.P.A.	Stable polymorph of flibanserin
US10675280B2 (en)	2001-10-20	2020-06-09	Sprout Pharmaceuticals, Inc.	Treating sexual desire disorders with flibanserin
UA78974C2 (en)	2001-10-20	2007-05-10	Boehringer Ingelheim Pharma	Use of flibanserin for treating disorders of sexual desire
MXPA04003866A (es) *	2001-11-09	2004-07-08	Pharmacia Ab	Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva.
GB0130219D0 (en) *	2001-12-18	2002-02-06	Pfizer Ltd	Compounds for the treatment of sexual dysfunction
GB0230036D0 (en) *	2002-12-23	2003-01-29	Pfizer Ltd	Novel pharmaceuticals
GB0230025D0 (en) *	2002-12-23	2003-01-29	Pfizer Ltd	Novel pharmaceuticals
PA8597401A1 (es) *	2003-03-14	2005-05-24	Pfizer	Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
US7427611B2 (en)	2003-09-26	2008-09-23	Solvay Pharmaceuticals Gmbh	Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7262184B2 (en)	2003-09-26	2007-08-28	Solvay Pharmaceuticals Gmbh	Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7452875B2 (en)	2003-09-26	2008-11-18	Solvay Pharmaceuticals Gmbh	Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7649002B2 (en)	2004-02-04	2010-01-19	Pfizer Inc	(3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
CN101027061B (zh)	2004-05-11	2014-03-12	情感智能有限责任公司	药物制剂及其在治疗女性性功能障碍中的应用
US20060025420A1 (en) *	2004-07-30	2006-02-02	Boehringer Ingelheimn International GmbH	Pharmaceutical compositions for the treatment of female sexual disorders
WO2006027680A1 (en) *	2004-09-10	2006-03-16	Pfizer Limited	3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
CA2617546C (en)	2005-08-03	2014-07-15	Boehringer Ingelheim International Gmbh	Use of flibanserin in the treatment of obesity
WO2007048803A1 (en)	2005-10-29	2007-05-03	Boehringer Ingelheim International Gmbh	Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
EP1790343A1 (en) *	2005-11-11	2007-05-30	Emotional Brain B.V.	Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
WO2008000760A1 (en)	2006-06-30	2008-01-03	Boehringer Ingelheim International Gmbh	Flibanserin for the treatment of urinary incontinence and related diseases
CA2660476C (en)	2006-08-14	2015-11-17	Boehringer Ingelheim International Gmbh	Formulations of flibanserin and method for manufacturing the same
WO2008022932A2 (en)	2006-08-25	2008-02-28	Boehringer Ingelheim International Gmbh	Controlled release system and method for manufacturing the same
JP2010508358A (ja) *	2006-11-01	2010-03-18	ブリストル−マイヤーズスクイブカンパニー	グルココルチコイド受容体、ＡＰ−１、および／またはＮＦ−κＢ活性の調節剤、並びにその使用
EP1925307A1 (en)	2006-11-03	2008-05-28	Emotional Brain B.V.	Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
PE20091188A1 (es)	2007-09-12	2009-08-31	Boehringer Ingelheim Int	Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
US8993631B2 (en)	2010-11-16	2015-03-31	Novartis Ag	Method of treating contrast-induced nephropathy
US8877815B2 (en) *	2010-11-16	2014-11-04	Novartis Ag	Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
WO2015089105A1 (en)	2013-12-09	2015-06-18	Respira Therapeutics, Inc.	Pde5 inhibitor powder formulations and methods relating thereto
HRP20191327T1 (hr)	2015-06-03	2019-11-01	Bristol Myers Squibb Co	4-hidroksi-3-(heteroaril)piridin-2-on apj agonisti za primjenju u liječenju kardiovaskularnih poremećaja
EP3554507A1 (en)	2016-12-14	2019-10-23	Respira Therapeutics, Inc.	Methods and compositions for treatment of pulmonary hypertension and other lung disorders
CN107746400A (zh) *	2017-12-04	2018-03-02	武汉药明康德新药开发有限公司	苯并二氢吡喃‑6‑磺酰氯的制备方法
CR20200464A (es)	2018-03-08	2021-04-14	Incyte Corp	Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
WO2020010003A1 (en)	2018-07-02	2020-01-09	Incyte Corporation	AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
CN110483403A (zh) *	2019-09-02	2019-11-22	南通大学	一种5-溴-4-甲氧基-1h-吲唑的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991010644A1 (en) *	1990-01-12	1991-07-25	Pfizer Limited	Cycloalkyl-substituted glutaramide diuretic agents
WO1991013054A1 (en) *	1990-02-26	1991-09-05	Pfizer Limited	Cycloalkyl-substituted glutaramide antihypertensive agents
WO1994006756A1 (en) *	1992-09-23	1994-03-31	Schering Corporation	N-(acylaminomethyl)glutaryl amino acids and their use as dual inhibitors of neutral endopeptidase and angiotensin converting enzyme

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5389610A (en)	1989-11-21	1995-02-14	Schering Corporation	Carboxyalkylcarbonyl aminoacid endopeptidase inhibitors
IL139455A0 (en)	1999-11-08	2001-11-25	Pfizer	Compounds for the treatment of female sexual dysfunction
US20020052370A1 (en) *	2000-07-06	2002-05-02	Barber Christopher Gordon	Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase

2002
- 2002-03-18 EE EEP200300469A patent/EE200300469A/xx unknown
- 2002-03-18 NZ NZ527012A patent/NZ527012A/en unknown
- 2002-03-18 MX MXPA03006597A patent/MXPA03006597A/es active IP Right Grant
- 2002-03-18 EP EP02707042A patent/EP1373192A1/en not_active Withdrawn
- 2002-03-18 IL IL15700902A patent/IL157009A0/xx unknown
- 2002-03-18 HU HU0303624A patent/HUP0303624A3/hu unknown
- 2002-03-18 KR KR1020037012690A patent/KR100564466B1/ko not_active Expired - Fee Related
- 2002-03-18 RS YU75303A patent/RS75303A/sr unknown
- 2002-03-18 CA CA002437113A patent/CA2437113A1/en not_active Abandoned
- 2002-03-18 HR HR20030751A patent/HRP20030751A2/xx not_active Application Discontinuation
- 2002-03-18 BR BR0208455-4A patent/BR0208455A/pt not_active IP Right Cessation
- 2002-03-18 DO DO2002000364A patent/DOP2002000364A/es unknown
- 2002-03-18 WO PCT/IB2002/000807 patent/WO2002079143A1/en not_active Ceased
- 2002-03-18 EA EA200300777A patent/EA006154B1/ru unknown
- 2002-03-18 SK SK1182-2003A patent/SK11822003A3/sk unknown
- 2002-03-18 CZ CZ20032534A patent/CZ20032534A3/cs unknown
- 2002-03-18 GE GE5313A patent/GEP20063783B/en unknown
- 2002-03-18 CN CNB028054091A patent/CN1243723C/zh not_active Expired - Fee Related
- 2002-03-18 JP JP2002577770A patent/JP4018545B2/ja not_active Expired - Fee Related
- 2002-03-18 OA OA1200300204A patent/OA12553A/en unknown
- 2002-03-18 PL PL02365101A patent/PL365101A1/xx not_active Application Discontinuation
- 2002-03-22 TW TW091105650A patent/TWI254038B/zh not_active IP Right Cessation
- 2002-03-25 UY UY27227A patent/UY27227A1/es not_active Application Discontinuation
- 2002-03-26 AR ARP020101114A patent/AR035795A1/es unknown
- 2002-03-26 PE PE2002000240A patent/PE20021014A1/es not_active Application Discontinuation
- 2002-03-26 MY MYPI20021077A patent/MY134081A/en unknown
- 2002-03-27 PA PA20028542401A patent/PA8542401A1/es unknown
- 2002-03-27 TN TNTNSN02032A patent/TNSN02032A1/fr unknown
- 2002-03-28 AP APAP/P/2002/002467A patent/AP1689A/en active
2003
- 2003-07-17 IS IS6877A patent/IS6877A/is unknown
- 2003-08-13 MA MA27280A patent/MA26996A1/fr unknown
- 2003-08-25 BG BG108130A patent/BG108130A/bg unknown
- 2003-09-26 NO NO20034299A patent/NO20034299L/no not_active Application Discontinuation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991010644A1 (en) *	1990-01-12	1991-07-25	Pfizer Limited	Cycloalkyl-substituted glutaramide diuretic agents
WO1991013054A1 (en) *	1990-02-26	1991-09-05	Pfizer Limited	Cycloalkyl-substituted glutaramide antihypertensive agents
WO1994006756A1 (en) *	1992-09-23	1994-03-31	Schering Corporation	N-(acylaminomethyl)glutaryl amino acids and their use as dual inhibitors of neutral endopeptidase and angiotensin converting enzyme

Also Published As

Publication number	Publication date
CA2437113A1 (en)	2002-10-10
AP2002002467A0 (en)	2002-06-30
WO2002079143A1 (en)	2002-10-10
BG108130A (bg)	2004-07-30
NZ527012A (en)	2005-03-24
NO20034299D0 (no)	2003-09-26
HK1060724A1 (en)	2004-08-20
MY134081A (en)	2007-11-30
TNSN02032A1 (fr)	2005-12-23
OA12553A (en)	2006-06-07
IS6877A (is)	2003-07-17
AR035795A1 (es)	2004-07-14
EP1373192A1 (en)	2004-01-02
KR100564466B1 (ko)	2006-03-29
EA200300777A1 (ru)	2003-12-25
NO20034299L (no)	2003-11-27
UY27227A1 (es)	2002-10-31
BR0208455A (pt)	2004-03-02
MA26996A1 (fr)	2004-12-20
HUP0303624A2 (hu)	2004-03-01
CZ20032534A3 (cs)	2004-07-14
HUP0303624A3 (en)	2005-06-28
CN1243723C (zh)	2006-03-01
HRP20030751A2 (en)	2005-08-31
GEP20063783B (en)	2006-04-10
TWI254038B (en)	2006-05-01
IL157009A0 (en)	2004-02-08
EE200300469A (et)	2004-02-16
PA8542401A1 (es)	2002-10-28
CN1492852A (zh)	2004-04-28
DOP2002000364A (es)	2002-10-15
JP2004531505A (ja)	2004-10-14
RS75303A (sr)	2006-12-15
JP4018545B2 (ja)	2007-12-05
MXPA03006597A (es)	2004-10-15
EA006154B1 (ru)	2005-10-27
SK11822003A3 (sk)	2004-09-08
KR20030092032A (ko)	2003-12-03
PE20021014A1 (es)	2002-11-12
PL365101A1 (en)	2004-12-27

Publication	Publication Date	Title
MY134081A (en)	2007-11-30	N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad.
PE20061417A1 (es)	2007-01-20	Metodo para sintetizar 3-cianoquinolinas sustituidas y sus intermediarios
DK1311272T3 (da)	2007-02-26	Hidtil ukendte fremgangsmåder hvor der anvendes cholinesteraseinhibitorer
DK0626853T3 (da)	2000-08-07	Anvendelse af substituerede adeninderivater til behandling af multipel sclerose
AR013184A1 (es)	2000-12-13	Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
DK0657428T3 (da)	2001-05-07	Fremstilling af 3,4,4-trisubstituerede-piperidinyl-N-alkylcarboxylater og mellemprodukter, der er egnede som opioidantagonister
AP1687A (en)	2006-12-04	Therapeutic biaryl derivatives.
ZA200609261B (en)	2008-08-27	Fused quinoline derivative and use thereof
ATE490788T1 (de)	2010-12-15	Antivirale phosphonate analoge
CY1107196T1 (el)	2012-11-21	Υποκατεστημενα παραγωγα 2,4-διϋδρο-πυρρολο (3,4-β) -κινολιν-9-ονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
EA200401160A1 (ru)	2005-02-24	Производные тиазола и оксазола, которые модулируют активность ppar
DK0700380T3 (da)	1998-11-09	N-Alkylthiopolyaminderivater som radioprotektive midler
ES2125441T3 (es)	1999-03-01	Analogos de acilfulveno como agentes antitumorales
MXPA05009660A (es)	2005-10-20	Derivados azabiciclicos de piridiloximetilo y bencisoxazol.
DK0503453T3 (da)	2001-07-16	Fremgangsmåde til fremstilling af cephalosporiner og mellemprodukter i denne fremgangsmåde
ES2058191T3 (es)	1994-11-01	Acidos 2-fenil-4-quinolincarboxilicos substituidos.
PL341539A1 (en)	2001-04-23	Heterocyclic toxins of topoisomerases
UY27413A1 (es)	2003-02-28	Agonistas de la oxitocina
WO2002060874A8 (en)	2003-02-20	Potassium channel inhibitors
IL112900A (en)	1997-06-10	Intermediates for the preparation of hiv protease inhibitors
KR950700684A (ko)	1995-02-20	시클릭 항-종양 촉진제 화합물, 그의 조성물, 제조 방법 및 용도(Cyclic Anti-Tumor Promoter Compounds, Compositions and Methods for Production and Use)
DK1049686T3 (da)	2006-01-16	Nyttige mellemprodukter og fremgangsmåder ved semisyntese af paclitaxel og analoger deraf
CO5200761A1 (es)	2002-09-27	Nuevos derivados de equinocandina, su procedimiento de preparacion y su aplicacion como antifungicos
CY1107287T1 (el)	2012-11-21	Χρηση της ερυθροποιητινης, καθως και παραγωγων αυτης για τη θεραπεια σχιζοφρενειων και συναφων ψυχωσεων
MX9304152A (es)	1994-04-29	Inhibidores de enzimas.